Drug Profile
QAN 747
Alternative Names: QAN747Latest Information Update: 11 May 2006
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 03 Jan 2006 Discontinued - Phase-I for Asthma (unspecified route)
- 03 Jan 2006 Discontinued - Phase-I for Chronic obstructive pulmonary disease (unspecified route)